Search Results
Oct 20, 2025, 06:02 ET Battery Recycling Market to Reach $77.1 billion, Globally, by 2034 at 11.2% CAGR: Allied Market Research
proposals), while maintaining high recovery rates for nickel, cobalt, and manganese at 98%. New targets of 98% are also set for copper, aluminum, and rare earth metals. Export of Recycled Batteries to Countries with Material Shortages
More news about: Allied Market Research
Oct 20, 2025, 06:00 ET IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
Skin Cancer Research for Sarah Cannon Research Institute and principal investigator on the trial. Metastatic uveal melanoma is a rare and aggressive form of ocular cancer with poor prognosis, where historical median OS reported in published meta-analysis from patients in the treatment
More news about: IDEAYA Biosciences, Inc.
Oct 20, 2025, 05:36 ET Battery Recycling Market to Reach $77.1 billion, Globally, by 2034 at 11.2% CAGR: Allied Market Research
proposals), while maintaining high recovery rates for nickel, cobalt, and manganese at 98%. New targets of 98% are also set for copper, aluminum, and rare earth metals. Export of Recycled Batteries to Countries with Material Shortages
More news about: Allied Market Research
Oct 20, 2025, 05:00 ET FDA Grants Orphan Drug Designation to Cellenkos' CK0803 Tregs for Treatment of Amyotrophic Lateral Sclerosis
This designation supports the development of medicines for rare disorders that affect fewer than 200,000 people in the U.S, and qualifies a company for incentives, including tax credits, exemptions from certain FDA
More news about: Cellenkos, Inc.
Oct 20, 2025, 02:37 ET Immunotherapy After Surgery Shows Promise in Treating Rare, Aggressive Skin Cancer
Oct. 20, 2025 /PRNewswire/ -- A drug that harnesses the immune system to attack cancer cells has proved successful in preventing a rare and aggressive form of skin cancer from spreading to other organs when given immediately after surgery, a new study shows.
More news about: NYU Langone Health System
Oct 20, 2025, 00:06 ET Une nouvelle ère pour les spiritueux de luxe commence : Les Jardins d'Arménie font leurs débuts à Monaco
s'agit d'un héritage culturel et d'un savoir-faire transmis de génération en génération. Avoir l'honneur de guider cette dégustation est un privilège rare", a déclaré Bruno Scavo, sommelier, journaliste Vins & Gastronomie. A propos des Jardins d'Arménie
More news about: Jardins d’Arménie
Oct 19, 2025, 16:01 ET Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK
More news about: Swedish Orphan Biovitrum AB
Oct 19, 2025, 15:59 ET Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK
More news about: Swedish Orphan Biovitrum AB
Oct 19, 2025, 02:00 ET Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex genetic abnormalities. There is currently no standard treatment regimens,
More news about: CARsgen Therapeutics
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRA
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The Company's lead product candidate is MOLBREEVI (also referred to as "molgramostim"), an inhaled granulocyte-macrophage colony-stimulating
More news about: Pomerantz LLP
Oct 17, 2025, 17:39 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and
More news about: Novo Nordisk
Oct 17, 2025, 17:15 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and
More news about: Novo Nordisk
Oct 17, 2025, 16:45 ET SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2)
More news about: THE ROSEN LAW FIRM, P. A.
Oct 17, 2025, 16:25 ET Liza Minnelli to Present Janet Jackson with the 2025 ICON Award at the Gala of the Stars Benefiting Dancers Against Cancer
feet, now returns to honor another boundary-breaking trailblazer. The union of these two legendary women—each redefining artistry in her own era—marks a rare and emotional convergence of music, movement, and enduring influence. Australian performer BP Major, Ms. Minnelli's Artistic
More news about: Dancers Against Cancer
Oct 17, 2025, 16:00 ET FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of
More news about: Amgen
Oct 17, 2025, 12:27 ET SIGMA LITHIUM ADDED TO MORGAN STANLEY NATIONAL SECURITY INDEX
First Quantum Minerals (copper), Cameco Corp (uranium), MP Materials (rare earths), Lithium Americas (lithium), Centrus Energy Corp (uranium), NioCorp Developments (rare earths), USA Rare Earth (rare earths), Ivanhoe Electric (rare earths), among others. The index also includes Tesla (technology, batteries).
More news about: Sigma Lithium Corporation
Oct 17, 2025, 12:00 ET Quilceda Creek releases rare library wines with goal of raising $250,000 for Cancer Research Institute
Awareness Month, Quilceda Creek President Paul Golitzin and General Manager Scott Lloyd announced today that beginning Oct. 27, the winery will release a rare collection of library wines in support of the Cancer Research Institute (CRI). Fifty percent from every bottle sold will be donated to CRI, with a fundraising
More news about: Quilceda Creek
Oct 17, 2025, 09:00 ET Asymmetric Capital Partners Announces $137 Million Fund II to Back Early Stage Founders
personal capital to Fund II, underscoring alignment with LPs and confidence in the long-term strategy. "I've seen firsthand how rare it is to find investors who combine high conviction with humility, speed, and strategic depth," said Chris Douvos, founder of Ahoy Capital, a Limited
More news about: Asymmetric Capital Partners
Oct 17, 2025, 09:00 ET Buscar Company announces the completion of the 43-101 report for its subsidiary Eon Discovery Inc.
$117.16 billion across Proven and Probable Reserves, based on certified multi-element assay data including gold, silver, platinum-group metals, and rare earth elements. This valuation underscores Treasure Canyon's position as a high-value, sustainable mining asset in the northern Sierra Nevada region.
More news about: Buscar Company (CGLD)
Oct 17, 2025, 08:00 ET Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at ESMO 2025
preliminary efficacy of invikafusp alfa as a monotherapy in biomarker-selected patients with advanced antigen-rich solid tumors, including PD-1 refractory and rare tumor types. The trial consists of two parts: Phase 1 dose escalation and Phase 2 dose expansion. For more information, visit
More news about: Marengo Therapeutics
Oct 17, 2025, 06:00 ET Magnesium Oxide (MgO) Market worth $6.31 billion by 2030 - Exclusive Report by MarketsandMarkets™
Rare Earth Metals Market - Global Forecast to 2030
More news about: MarketsandMarkets
Oct 17, 2025, 05:00 ET Rebecca Rau Jewels Unveils the THEN & NOW Collection, a Fusion of Ancient Artifacts and Modern Adornment
A rare collection blending rare ancient artifacts with modern gemstones previews at M.S. Rau in New Orleans, followed by an exclusive NYC Jewelry Week collection launch. NEW YORK, Oct.
More news about: Rebecca Rau Jewels
Oct 17, 2025, 04:38 ET Duchenne Muscular Dystrophy Therapeutics Market Surges Toward $6.6B by 2033 as Gene and RNA Therapies Redefine Treatment Paradigm | by DataM Intelligence
$491.7 million revenue in 2024, leveraging rare disease expertise to expand into DMD. Nippon Shinyaku (NS Pharma) - Strengthening global presence with Viltepso; a cornerstone of Japan's rare disease portfolio.
More news about: DataM Intelligence 4 Market Research LLP
Oct 17, 2025, 02:00 ET Renalys Pharma Reaches Japan PMDA Agreement on Phase III Clinical Trials of Sparsentan for Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS)
end-stage renal disease in male patients during late adolescence or early adulthood and may also present with hearing loss or ocular symptoms. As a rare disease (designated intractable disease No. 218), AS remains without an established curative treatment, and effective therapeutic options are urgently
More news about: Renalys Pharma, Inc.
Oct 17, 2025, 01:32 ET FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States
[2] Pediatric UV is a rare eye inflammation in children, representing 5–10% of all uveitis cases in the U.S., while HS affects approximately 1–4% of the U.S. population
More news about: Celltrion USA